/PTIX
PTIX Stock - Protagenic Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$1.19-7.75%
$0.10 (-7.75%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.31
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PTIX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.18 – $1.20
TARGET (TP)$1.37
STOP LOSS$1.09
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.47
52W High$14.28
52W Low$1.19
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-50,286 | $-28,218 | $-30 | N/A | $-286 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-5,701,000 | $-4,527,000 | $-3,558,000 | $-4,140,000 | $-2,552,000 |
| Net Income | $-5,525,000 | $-5,000,000 | $-3,556,000 | $-4,523,000 | $-2,548,735 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.13 | $-1.15 | $-0.82 | $-1.24 | $-1.00 |
Company Overview
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
PTIXBeat Rate
0%
Last 2 quarters
Avg Surprise
-3205.6%
EPS vs Estimate
Beats / Misses
0/2
Last 12 quarters
Latest EPS
$-0.47
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | — | — | — | — |
Q4 2025 | Nov 26, 2025 | — | $-0.47 | — | — |
Q3 2025 | Aug 18, 2025 | — | $-1.37 | — | — |
Q2 2025 | May 13, 2025 | — | $-2.75 | — | — |
Q1 2025 | Mar 31, 2025 | — | $-3.36 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-1.96 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-5.04 | — | — |
Q2 2024 | May 15, 2024 | — | $-5.46 | — | — |
Q2 2024 | Apr 1, 2024 | — | $-5.32 | — | — |
Q4 2023 | Nov 14, 2023 | — | $-4.48 | — | — |
Q3 2023 | Aug 14, 2023 | — | $-3.92 | — | — |
Q2 2023 | May 15, 2023 | — | $-2.38 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.14 | — | — |
Q4 2022 | Nov 14, 2022 | — | $-2.80 | — | — |
Q3 2022 | Aug 11, 2022 | — | $-2.24 | — | — |
Q2 2022 | May 13, 2022 | — | $-4.48 | — | — |
Q2 2022 | Apr 7, 2022 | $-0.09 | $-2.80 | -3011.1% | ✗ MISS |
Q4 2021 | Nov 16, 2021 | $-0.08 | $-2.80 | -3400.0% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | — | $-6.16 | — | — |
Q2 2021 | May 17, 2021 | — | $-6.16 | — | — |
Latest News
Protagenic Therapeutics Reports Topline Phase 1 Safety Data For PT00114, Was Well Tolerated Across All Dose Ranges Studied; Paves Way For Phase 2 In Stress-Related Neuropsychiatric Conditions
📈 PositiveBenzinga•Dec 9, 2025, 01:48 PM
Protagenic Therapeutics Completes Enrollment, Dosing In Its Multiple Ascending Dose Phase 1 Trial Evaluating PT00114
📈 PositiveBenzinga•Nov 13, 2025, 01:26 PM
Protagenic Therapeutics shares are trading lower after the company filed a complaint to rescind its share exchange agreement by which it acquired Phytanix Bio.
📉 NegativeBenzinga•Nov 3, 2025, 02:24 PM
Protagenic Therapeutics Files Complaint To Rescind Share Exchange Agreement By Which Co Acquired Phytanix Bio
📉 NegativeBenzinga•Oct 31, 2025, 09:33 PM
Protagenic Therapeutics May Offer And Sell Shares Of Common Stock Of Up To $1.75M
➖ NeutralBenzinga•Oct 24, 2025, 09:44 PM
Protagenic Therapeutics shares are trading higher after the company announced it expects to file its Quarterly Report on Form 10-Q for the period ended June 30, 2025 in the near future, following a delay attributable to the completion of merger-related consolidation of financial statements, including purchase accounting adjustments, pro forma financial information, and related disclosures.
📈 PositiveBenzinga•Aug 25, 2025, 05:04 PM
Protagenic Therapeutics Expects To File Its Quarterly Report On Form 10-Q For The Period Ended June 30, 2025 In The Near Future, Following A Delay Attributable To The Completion Of Merger-Related Consolidation Of Financial Statements, Including Purchase Accounting Adjustments, Pro Forma Financial Information, And Related Disclosures
➖ NeutralBenzinga•Aug 22, 2025, 09:28 PM
Protagenic Therapeutics shares are trading higher after the company announced it has completed the first dose injections in its Phase 1 multiple-dose study of PT00114.
📈 PositiveBenzinga•Aug 21, 2025, 12:21 PM
Protagenic Completes First Dose Injections In Phase I Multiple-Dose Study Of PT00114; Topline Safety Data Expected By September; Phase 2 Launch Targeted For Q1 2026
📈 PositiveBenzinga•Aug 21, 2025, 12:16 PM
Frequently Asked Questions about PTIX
What is PTIX's current stock price?
Protagenic Therapeutics, Inc. (PTIX) is currently trading at $1.19 per share. The stock has moved -7.75% today.
What is the analyst price target for PTIX?
No analyst price targets are currently available for this stock.
What sector is Protagenic Therapeutics, Inc. in?
Protagenic Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PTIX's market cap?
Protagenic Therapeutics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does PTIX pay dividends?
No, Protagenic Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARTL
Artelo Biosciences, Inc.
$1.57
Mkt Cap: $0.0B
CARM
Carisma Therapeutics, Inc.
$0.05
Mkt Cap: $0.0B
GTBP
GT Biopharma, Inc.
$0.76
Mkt Cap: $0.0B
INDP
Indaptus Therapeutics, Inc.
$2.03
Mkt Cap: $0.0B
LIPO
Lipella Pharmaceuticals Inc.
$0.21
Mkt Cap: $0.0B
PBM
Psyence Biomedical Ltd.
$1.00
Mkt Cap: $0.0B
REVB
Revelation Biosciences, Inc.
$0.89
Mkt Cap: $0.0B
SLRX
Salarius Pharmaceuticals, Inc.
$0.69
Mkt Cap: $0.0B
SLXN
Silexion Therapeutics Ltd.
$2.40
Mkt Cap: $0.0B
SPRC
SciSparc Ltd.
$1.46
Mkt Cap: $0.0B
Explore stocks similar to PTIX for comparison